CRBP

About CRBP

Corbus Pharmaceuticals Holdings, Inc. is focused on the development of immune modulators that have application in disease states spanning from immuno-oncology to fibrosis. The Company’s pipeline includes anti-integrin monoclonal antibodies that block activation of TGFβ and small molecules that activate or inhibit the endocannabinoid system. The Company pipeline includes Anti-integrin monoclonal antibodies (mAbs), Cannabinoid receptor type 1 (CB1) and Lenabasum. The mAbs is for the treatment of cancer and fibrosis that inhibit the activation of Transforming growth factor β (TGFβ). Its CRB-601 is an anti-αvβ8 mAb being developed as a potential treatment for solid tumors in combination with existing therapies, including checkpoint inhibitors. Cannabinoid receptor type 1 (CB1) is an inverse agonist designed to treat obesity and related metabolic diseases. Lenabasum is a novel, synthetic, oral molecule that selectively activates cannabinoid receptor type 2 (CB2).